Trial Profile

Comparative efficacy of rivaroxaban and warfarin to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation in a real world setting.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Aug 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Warfarin
Indications Gastrointestinal haemorrhage; Intracranial haemorrhages; Stroke; Venous thromboembolism
Focus Adverse reactions; Therapeutic Use
Sponsors Janssen

Most Recent Events

09 Aug 2014 New trial record
04 Jun 2014 Results presented at the 19th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com